TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4680-4686

  Andries, Koen ^a   Azijn, Hilde ^b   Thielemans, Theo ^a   Ludovici, Donald ^c   Kukla, Michael ^c   Heeres, Jan ^d   Janssen, Paul ^d   De Corte, Bart ^c   Vingerhoets, Johan ^b   Pauwels, Rudi ^b   De Béthune, Marie Pierre ^b,e  

^a A Division of Johnson Johnson   (Belgium)

^b Virco BVBA   (Belgium)

^c Johnson Johnson P   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ETRAVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL FRACTIONATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INCUBATION TIME; INTERMETHOD COMPARISON; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ANALYSIS; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

CELL LINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSOMES, LIVER; MUTAGENESIS, SITE-DIRECTED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 9644291579     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4680-4686.2004     Document Type: Article

References (29)

1. Antinori, A., M. Zaccarelli, A. Cingolani, F. Forbici, M. G. Rizzo, M. P. Trotta, S. Di Giambenedetto, P. Narciso, A. Ammassari, E. Girardi, A. De Luca, and C. F. Perno. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recyding efavirenz after nevirapine failure. AIDS Res. Hum. Retrovir. 18:835-838.
2. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
3. Balotta, C., G. Facchi, M. Violin, S. Van Dooren, A. Cozzi-Lepri, F. Forbici, A. Bertoli, C. Riva, D. Senese, P. Caramello, G. Carnevale, G. Rizzardini, L. Cremonini, L. Monno, G. Rezza, C. F. Perno, G. Ippolito, A. d'Arminio-Monforte, A. M. Vandamme, and M. Moroni. 2001. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 27:499-505.
4. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
5. Bohets, H., K. Lavrijsen, J. Hendrickx, J. van Houdt, V. van Genechten, P. Verboven, W. Meuldermans, and J. Heykants. 2000. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br. J. Pharmacol. 129:1655-1667.
6. Brennan, T. M., D. L. Taylor, C. G. Bridges, J. P. Leyda, and A. S. Tyms. 1995. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antivir. Res. 26:173-187.
7. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
8. Corbett, J. W., S. S. Ko, J. D. Rodgers, S. Jeffrey, L. T. Bacheler, R. M. Klabe, S. Diamond, C.-M. Lai, S. R. Rabel, J. A. Saye, S. P. Adams, G. L. Trainor, P. S. Anderson, and S. K. Erickson-Viitanen. 1999. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43:2893-2897.
9. Das, K., A. D. Clark, P. J. Lewi, J. Heeres, M. R. De Jonge, L. M. Koymans, H. M. Vinkers, F. Daeyaert, D. W. Ludovici, M. J. Kukla, B. De Corte, R. W. Kavash, C. Y. Ho, H. Ye, M. A. Lichtenstein, K. Andries, R. Pauwels, M. P. De Béthune, P. L. Boyer, P. Clark, S. H. Hughes, P. A. Janssen, and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
10. Decks, S. G. 2001. International perspectives on antiretroviral resistance: nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S25-S33.
11. Delaugerre, C., R. Rohban, A. Simon, M. Mouroux, C. Tricot, R. Agher, J. M. Huraux, C. Katlama, and V. Calvez. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 65:445-448.
12. Delwart, E. L., E. G. Shpaer, J. Louwagie, F. E. McCutchan, M. Grez, H. Rubsamen-Waigmann, and J. I. Mullins. 1993. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262:1257-1261.
13. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1997. DAIDS virology manual for HIV Laboratories. Publication NIH-97-3828. U.S. Department of Health and Human Services, Washington, D.C.
14. Fields, R. D., and M. V. Lancaster. 1993. Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am. Biotechnol. Lab. 11:48-50.
15. Gazzard, B., A. Pozniak, W. Rozenbaum, P. Yeni, S. Staszewski, K. Arasteh, K. De Dier, M. Peeters, B. Woodfall, J. Stebbing, and G. A. E. van't Klooster. 2003. An open-label assessment of TMC 125: a new, next generation NNRTI, for 7 days in HIV-1-infected individuals with NNRTI resistance. AIDS 17:F49-F54.
16. Gruzdev, B., A. Rakhmanova, E. Doubovskaya, A. Yakovlev, M. Peeters, A. Rinehart, K. De Dier, P. Baede-Van Dijk, W. Parys, and G. van't Klooster. 2003. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1-infected subjects. AIDS 17:2487-2494.
17. Harrigan, P. R., and B. A. Larder. 2002. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob. Agents Chemother. 46:909-912.
18. Hertogs, K., M. P. de Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
19. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
20. Leigh-Brown, A. J., S. D. Frost, W. C. Mathews, K. Dawson, N. S. Hellmann, E. S. Daar, D. D. Richman, and S. J. Little. 2003. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis. 187:683-686.
21. Ludovici, D. W., B. L. De Corte, M. J. Kukla, H. Ye, C. Y. Ho, M. A. Lichtenstein, R. W. Kavash, K. Andries, M. P. de Bethune, H. Azijn, R. Pauwels, P. J. Lewi, J. Heeres, L. M. Koymans, M. R. de Jonge, K. J. Van Aken, F. F. Daeyaert, K. Das, E. Arnold, and P. A. Janssen. 2001. Evolution of anti-HIV drug candidates. 3. Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 11:2235-2239.
22. Ludovici, D. W., R. W. Kavash, M. J. Kukla, C. Y. Ho, H. Ye, B. L. De Corte, K. Andries, M. P. de Bethune, H. Azijn, R. Pauwels, H. E. Moereels, J. Heeres, L. M. Koymans, M. R. de Jonge, K. J. Van Aken, F. F. Daeyaert, P. J. Lewi, K. Das, E. Arnold, and P. A. Janssen. 2001. Evolution of anti-HIV drug candidates. 2. Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 11:2229-2234.
23. Ludovici, D. W., M. J. Kukla, P. G. Grous, S. Krishnan, K. Andries, M. P. de Bethune, H. Azijn, R. Pauwels, E. De Clercq, E. Arnold, and P. A. Janssen. 2001. Evolution of anti-HIV drug candidates. 1. From alpha- anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 11:2225-2228.
24. Moyle, G. 2001. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs 61:19-26.
25. Oie, S., M. A. Jacobson, and D. I. Abrams. 1993. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 6:531-533.
26. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
27. Perno, C. F., and R. Yarchoan. 1993. Culture of HIV in monocytes and macrophages, p. 12.4.1-12.4.11. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology, vol. 3. John Wiley & Sons, Inc., New York, N.Y.
28. Perrin, L., L. Kaiser, and S. Yerly. 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-27.
29. Tanaka, H., H. Takashima, M. Ubasawa, K. Sekiya, N. Inouye, M. Baba, S. Shigeta, R. T. Walker, E. De Clercq, and T. Miyasaka. 1995. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-5- (phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 38:2860-2865.